Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arnebia Indigo Jade Pearl (AIJP) is an investigational Chinese herbal topical cream developed for the treatment of anal high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer. The formulation is based on traditional Chinese medicine (TCM) and contains extracts from *Arnebia euchroma* (Zicao), *Indigo naturalis* (Qingdai), and other ingredients such as pearl powder and nephrite (jade). AIJP is hypothesized to work through anti-inflammatory, antiviral, and antiproliferative mechanisms, specifically targeting cells infected with high-risk human papillomavirus (HPV). It is primarily being studied in HIV-positive populations as a topical, patient-applied or clinician-applied alternative to invasive procedures like infrared coagulation or surgical excision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Arnebia Indigo Jade Pearl.